

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

14th August, 2019

The Secretary National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 Trading Symbol: AGLSL	The Secretary BSE Ltd PhirozeJeejeebhoy Towers, Dalal Street, Mumbai - 400001 Scrip Code:540616
--	--

Sub: Outcome of the Board Meeting held on 14th August, 2019

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Board of Directors of the Company in their meeting held on 14.08.2019 have inter alia, considered and approved the following:

Approved the Unaudited Financial results (Standalone and Consolidated) for the quarter ended 30th June, 2019 as recommended by the Audit Committee.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results (Standalone and Consolidated), along with the Limited Review report by statutory auditor of the Company thereon, are attached herewith.

The Board Meeting commenced at 7:30 AM and concluded at 8:00 AM.

Please take the above information on your records.

Thanking you
Yours Faithfully

For Artemis Global Life Sciences Limited



Anuj Sood
Company Secretary (F10162)
414, 4th Floor, DDA Building No. 1
District Centre, Janakpuri, New Delhi-58

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Email: anand.dua@gmail.com
Ph: 47021279

Review report

To
The Board of Directors
Artemis Global Life Sciences Limited


We have reviewed the accompanying statement of unaudited financial results of Artemis Global Life Sciences Limited ('the Company') for the quarter ended 30th June, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 14/08/2019

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N


(Anand Dua)
Partner
M.No. 083503

UDIN - 19083503 AAAA ZN6073

Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To


The Board of Directors

Artemis Global Life Sciences Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Artemis Global Life Sciences Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30th June, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30th June, 2018, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 1. Artemis Health Sciences Limited (100% Subsidiary)
 2. Artemis Medicare Services Limited (100% Subsidiary of Artemis Health Sciences Limited)
 3. Athena Eduspark Limited (100% Subsidiary of Artemis Health Sciences Limited)
 4. Artemis Cardiac Care Private Limited (Subsidiary of Artemis Medicare Services Limited holding 65% of Equity Shares)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Attention is drawn to Note No. 4 of the unaudited consolidated financial results informing that Composite Scheme of Amalgamation for amalgamating Aretmis Health Science Limited, Artemis Medicare Services Limited and Athena Eduspark Limited with the Parent company was filed with the National Company Law Tribunal New Delhi Bench -III, at New Delhi (NCLT). NCLT reserved the order for pronouncement, subject to clarification on August 1, 2019.

Our conclusion is not modified in respect of this matter.

7. We did not review the interim financial results of four subsidiaries (including step down subsidiaries) included in the Group, whose results reflect total revenues of Rs. 13,570.76 lakhs, total net profit after tax of Rs. 438.30 lakhs and total comprehensive income of Rs. 437.18 lakhs for the quarter ended as considered in the consolidated unaudited financial results of the entities included in the Group. The interim financial results of these subsidiaries have been reviewed by the other auditors whose reports have been furnished to us, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

Place: New Delhi
Date: 14/08/2019

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N


(Anand Dua)
Partner
M.No. 083503

UDIN-19983503AAAA209488

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

S No	Particulars	(Rs. in Lakh)			
		Quarter ended			Year ended
		30-Jun-19 (Unaudited)	31-Mar-19 (Audited) (Refer note 4)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
1	Revenue from operations*	10.20	10.20	10.20	40.80
2	Other income	-	-	-	-
3	Total Income	10.20	10.20	10.20	40.80
	Expenses				
	Employee Benefits expenses	9.43	6.32	6.15	24.84
	Finance costs	-	-	-	-
	Depreciation and amortization expense	3.76	3.73	3.76	15.10
	Other expenses	6.91	7.09	8.23	40.20
4	Total expenses	20.10	17.13	18.14	80.14
5	Profit/(Loss) before Tax and exceptional items	(9.90)	(6.93)	(7.94)	(39.34)
6	Exceptional Items	-	-	-	-
7	Profit before tax	(9.90)	(6.93)	(7.94)	(39.34)
8	Tax Expense				
	Current Tax	-	-	-	-
	Deferred tax	1.80	(21.46)	(2.07)	(27.65)
	Total tax expense	1.80	(21.46)	(2.07)	(27.65)
9	Profit for the period	(11.70)	14.53	(5.87)	(11.69)
10	Other comprehensive income				
I	Items that will not be reclassified to profit or loss				
a	gains / (losses) on defined benefit plans	-	-	-	-
b	Deferred tax adjustment on revaluation	-	-	-	-
c	Income tax relating to items that will not be reclassified to profit & loss	-	-	-	-
II	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	-	-	-	-
	Other comprehensive income for the period, net of income tax	-	-	-	-
11	Total comprehensive income/(loss) ('OCI')	(11.70)	14.53	(5.87)	(11.69)
12	Paid up equity share capital (Face value Rs. 2/- each)	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserve (as per balance sheet of previous accounting year)	**	**	**	14,518.23
14	Earning per share (Face value Rs. 2/- each) (refer note 7)				
	Basic (Rs.)	(0.02)	0.02	(0.01)	(0.02)
	Diluted (Rs.)	(0.02)	0.02	(0.01)	(0.02)

* Medical Equipment Lease rentals received from Artemis Medicare Services Ltd.

** Not required to be shown




Notes

1. The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
2. The Company (AGLSL), Artemis Health Science Ltd. (AHSL), Artemis Medicare Services Ltd. (AMSL) and Athena Eduspark Ltd. (AEL), in their respective meeting held on 9th May, 2018, approved the draft Composite Scheme of Amalgamation between the AGLSL, AHSL AMSL and AEL and their respective shareholders & creditors, the same has also been filed with Bombay stock Exchange (BSE) and National Stock exchange (NSE) for their approval. The BSE and NSE vide their letters dated 5th September 2018 & 14th September, 2018 respectively had communicated to the company that they have no adverse observation on the Composite Scheme of Amalgamation. Subsequently, to the stock exchange approval the Composite Scheme of Amalgamation was filed with the National Company Law Tribunal New Delhi Bench -III, at New Delhi (NCLT). NCLT reserved the order for pronouncement, subject to clarification on August 1, 2019.
3. The above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under 133 of the companies act 2013, and the other recognised accounting practices and policies to the extent applicable.
4. The figures for the quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial yearended March 31, 2019 and the unaudited published year to date figures up to December 31, 2018 being the date of the end of third quarter of the previous financial year, which were subject to limited review.
5. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.
6. The above results for the quarter ended 30th June, 2019 were reviewed by the Audit Committee meeting held on August 13th, 2019 and approved by the Board of Directors meeting held on August 14th, 2019. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.



PLACE: NEW DELHI
DATE: AUGUST 14, 2019

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED


ONKAR S KANWAR
CHAIRMAN

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30,2019

(₹ in Lakh)

S No.	Particulars	Artemis Global Life Sciences Ltd			
		Quarter ended		Year ended	
		30-Jun-19 (Unaudited)	31-Mar-19 (Audited) (Refer note 6)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
1	Revenue from operations	13,570.76	14,015.70	12,643.07	54,651.59
2	Other income	59.01	131.27	116.86	400.21
3	Total Income	13,629.77	14,146.97	12,759.93	55,051.80
	Expenses				
	Purchases of pharmacy drugs & medical consumables	3,369.08	3,349.24	2,991.29	12,940.94
	Purchases of Stock in Trade	30.56	33.84	28.62	145.16
	Changes in inventories of pharmacy drugs, Medical consumables & Stock in Trade	(9.46)	22.79	10.66	(27.72)
	Employee benefit expenses	2,506.57	2,530.08	2,356.49	9,728.18
	Finance Cost	327.51	288.25	202.94	1,099.71
	Depreciation and amortization expense	545.39	519.89	490.25	2,007.44
	Other Expenses	6,194.35	6,288.73	6,083.66	25,483.62
4	Total expenses	12,964.00	13,032.82	12,163.91	51,377.33
5	Profit before exceptional items and tax	665.77	1,114.15	596.02	3,674.47
6	Exceptional items	-	-	-	-
7	Profit before Tax	665.77	1,114.15	596.02	3,674.47
	Tax Expense				
	Current Tax	287.14	336.71	259.14	1,377.75
	Deferred Tax	(47.97)	230.05	(28.55)	257.86
8	Total Tax Expense	239.17	566.76	230.59	1,635.61
9	Profit for the period	426.60	547.39	365.43	2,038.86
10	Other comprehensive income				
I	Items that will not be reclassified to profit or loss				
a	gains / (losses) on defined benefit plans	(14.16)	(48.66)	(4.39)	(56.65)
b	Deferred tax adjustment on revaluation	8.09	6.78	6.78	27.11
c	Income tax relating to items that will not be reclassified to profit & loss	4.95	17.00	1.53	19.79
	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	(1.12)	(24.88)	3.92	(9.75)
II					
11	Total comprehensive income for the period	425.48	522.51	369.35	2,029.11
12	Paid up equity share capital (Face value Rs. 10/- each)	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserves (as per balance sheet of previous accounting year)	**	**	**	21,444.45
14	Earning per share (Face value Rs. 10/- each)				
	Basic (Rs.)	0.64*	0.84*	0.55*	3.10
	Diluted (Rs.)	0.64*	0.84*	0.55*	3.10

* Not annualised

** Not required to be shown



De

Notes:-

1. The above results for the quarter ended 30th June, 2019 were reviewed by the Audit Committee meeting held on August 13th, 2019 and approved by the Board of Directors meeting held on August 14th, 2019. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.

2. The Group has adopted Ind AS 116 "Leases" effective 1 April 2019, as notified by the Ministry of Corporate Affairs (MCA) in the Companies (Indian Accounting Standard) Amendment Rules, 2019, retrospectively, with the cumulative effect of initially applying the standard recognised at the date of Initial application, with right to use asset being recognized at an amount equal to the lease liability, adjusted by the prepaid lease rent. This has resulted in the net impact of increase in the statement of Profit and Loss by Rs. 24.28 Lakh and Rs. 35.01 Lakh in the Depreciation and Finance cost respectively and a decrease in lease rent cost of Rs. 33.85 Lakh for the quarter ended 30th June, 2019.

3. Segment ReportingBusiness segment

The company's operation predominantly comprise of only one business segment- Income from Healthcare services.

Geographical information

Geographical information analyses the company's revenue by the Company's country of domicile (i.e. India)

Region	Quarter ended			Year ended
	30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
India	9,039.93	8,912.20	7,760.80	33,342.28
Outside India	4,530.83	5,103.50	4,882.27	21,309.31
Total	13,570.76	14,015.70	12,643.07	54,651.59

4. The Company (AGLSL), Aretmis Health Science Ltd. (AHSL), Artemis Medicare Services Ltd. (AMSL) and Athena Eduspark Ltd. (AEL), in their respective meeting held on 9th May, 2018, approved the draft Composite Scheme of Amalgamation between the AGLSL, AHSL AMSL and AEL and their respective shareholders & creditors, the same has also been filed with Bombay stock Exchange (BSE) and National Stock exchange (NSE) for their approval. The BSE and NSE vide their letters dated 5th September 2018 & 14th September, 2018 respectively had communicated to the company that they have no adverse observation on the Composite Scheme of Amalgamation.

Subsequently, to the stock exchange approval the Composite Scheme of Amalgamation was filed with the National Company Law Tribunal New Delhi Bench -III, at New Delhi (NCLT). NCLT reserved the order for pronouncement, subject to clarification on August 1, 2019.

5. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

6. The figures for the quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2019 and the unaudited published year to date figures up to December 31, 2018 being the date of the end of third quarter of the previous financial year, which were subject to limited review.

7. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.

For and on behalf of the Board of Directors of

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

Onkar S Kanwar

ONKAR S KANWAR
CHAIRMAN

PLACE: NEW DELHI
DATE: AUGUST 14, 2019



ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019				
RS. LAKH				
SL.NO.	P A R T I C U L A R S	QUARTER ENDED		YEAR ENDED
		30.06.2019	30.06.2018	31.03.2019
		(UNAUDITED)	(UNAUDITED)	(AUDITED)
1	Total Income from Operations	13,570.76	12,643.07	54,651.59
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Item)	665.77	596.02	3,674.47
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Item)	665.77	596.02	3,674.47
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Item)	426.60	365.43	2,038.86
5	Total Comprehensive Income for the period [comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	425.48	369.35	2,029.11
6	Paid-up Equity Share Capital (Equity Shares of Rs.2/-each)	1323.77	1,323.77	1,323.77
	(a) Basic	0.64	0.55	3.10
	(b) Diluted	0.64	0.55	3.10

NOTES:

The key standalone financial information of the Company is as under:

RS. LAKH				
SL.NO.	P A R T I C U L A R S	QUARTER ENDED		YEAR ENDED
		30.06.2019	30.06.2018	31.03.2019
		(UNAUDITED)	(UNAUDITED)	(AUDITED)
1	Total Income from Operations	10.20	10.20	40.80
2	Net Profit/(Loss) for the period Before Tax After Exceptional Item	(9.90)	(7.94)	(39.34)
3	Net Profit/(Loss) for the period After Tax	(11.70)	(5.87)	(11.69)

The above is an extract of the detailed format of Quarter ended Financial Results filed with the Stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results (Consolidated/ Standalone) are available on the stock exchanges websites, www.nseindia.com and www.bseindia.com and on the company's website www.aglsl.in

The above results for the quarter ended 30th June, 2019 were reviewed by the Audit Committee meeting held on August 13th, 2019 and approved by the Board of Directors meeting held on August 14th, 2019. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.

The above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED



Onkar S. Kanwar

ONKAR S. KANWAR
CHAIRMAN

PLACE: NEW DELHI
DATE: AUGUST 14, 2019